
    
      In this study, the investigator will assess progression-free and overall survival of patients
      with advanced renal cell carcinoma treated with 5-azacitidine in combination with
      bevacizumab. Patients will continue on treatment until either disease progression or
      development of other criteria for withdrawal.
    
  